In this study, we show that breast tumors from BRCA2 999del5 mutation carriers, displaying luminal- or basal/triple-negative phenotypes (TNPs), differ with respect to patterns of copy-number changes and markers of pRb/p16 pathway dysfunction, suggesting divergent paths of tumor evolution. This evidence concerns the gene BRCA2 and breast neoplasm.